GEO DataSets

Analysis of lesional and non-lesional skin biopsies from Atopic Dermatitis patients following NB-UVB phototherapy. Results identify a set of biomarkers of disease response to NB-UVB phototherapy.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 10 individual, 9 other, 2 protocol, 2 tissue sets

Platform:

GPL570

Series:

GSE27887

35 Samples

Download data: CEL

(Submitter supplied) Background: Atopic dermatitis (AD) is a common inflammatory skin disease exhibiting a predominantly Th2/“T22” immune activation and a defective epidermal barrier. Narrow-band UVB (NB-UVB) is considered an efficient treatment for moderate to severe AD. In psoriasis, NB-UVB has been found to suppress the Th1/Th17 immune polarization with subsequent reversal of epidermal hyperplasia. The immunomodulatory effects of this treatment are largely unknown in AD. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4444

Platform:

GPL570

35 Samples

Download data: CEL

(Submitter supplied) After 2 and 12 weeks of treatment, we observed significant reductions of 51% and 72%, respectively, in SCORAD scores. Clinical improvements were associated with significant gene expression changes in lesional but also nonlesional skin, particularly reductions in levels of TH2-, TH22-, and some TH17-related molecules (ie, IL-13, IL-22, CCL17, S100As, and elafin/peptidase inhibitor 3), and modulation of epidermal hyperplasia and differentiation measures.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

109 Samples

Download data: CEL

(Submitter supplied) Background: Atopic dermatitis (AD) is a common inflammatory skin disease with broad impact on quality of life and on the health care system. The pathophysiology is not fully understood, but it is likely multifactorial involving immune dysfunction, altered skin barrier and environmental factors. Narrow band ultraviolet B (nb-UVB) treatment leads to normalization of the tissue and clinical improvement. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL23159

91 Samples

Download data: CEL

(Submitter supplied) Atopic dermatitis (AD) is a common inflammatory skin disease with a T(H)2 and T22 immune polarity. Despite recent data showing a genetic predisposition to epidermal barrier defects in some patients, a fundamental debate still exists regarding the role of barrier abnormalities versus immune responses in initiating the disease. An extensive study of nonlesional AD (ANL) skin is necessary to explore whether there is an intrinsic predisposition to barrier abnormalities, background immune activation, or both in patients with AD. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4491

Platform:

GPL570

33 Samples

Download data: CEL

Analysis of paired samples of nonlesional atopic dermatitis (ANL) and lesional atopic dermatitis (AL) skin lesions compared with normal skin. ANL skin is characterized by terminal differentiation defects. Results provide insight into molecular mechanisms that characterize ANL skin.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 3 disease state, 22 individual, 14 other sets

Platform:

GPL570

Series:

GSE32924

33 Samples

Download data: CEL

(Submitter supplied) We conducted a randomized, double-blind, placebo-controlled trial in adults with moderate-to-severe AD unresponsive to conventional topical or systemic treatment. Fezakinumab (ILV-094; anti IL-22 monoclonal antibody) monotherapy was administered for 12 weeks (primary endpoint), and clinical responses were followed until week 20. AD transcriptome significantly improved at week 12 in fezakinumab vs. placebo (p<1E-18).

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

302 Samples

Download data: CEL

(Submitter supplied) We conducted a randomized, double-blind, placebo-controlled trial in adults with moderate-to-severe AD to test the efficacy of JAK/SYK-inhibitor ASN002. ASN002 significantly suppressed key AD inflammatory pathways, corresponding to clinical response, and may be an effective novel therapeutic agent for moderate-to-severe AD.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

111 Samples

Download data: CEL

(Submitter supplied) Background: Dupilumab is an IL-4 receptor a mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases. Objective: This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, and effects of dupilumab on molecular/cellular lesional and nonlesional skin phenotypes and systemic type 2 biomarkers of patients with moderate-to-severe atopic dermatitis (AD). more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

208 Samples

Download data: CEL

(Submitter supplied) Genome-Wide Profiling of Lesional and Non-Lesional Skin from Atopic Dermatitis, Psoriasis, and Contact Dermatitis Skin

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6480

75 Samples

Download data: TXT

(Submitter supplied) Atopic dermatitis (AD) is a common disease, with an increasing prevalence. The primary pathogenesis of the disease is still elusive, resulting in lack of specific treatments. The prevailing view is that AD is a biphasic, T-cell polarized disease, with Th2 predominating acute AD, and a switch to Th1 characterizing chronic disease. Identification of factors that participate in onset of lesions and maintenance of chronic lesions is critical for development of targeted therapeutics. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

39 Samples

Download data: CEL

(Submitter supplied) Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). The mechanism of action (MOA) of crisaborole and its effects on lesional measures of disease severity are not yet well-defined. This phase 2a, single-center, vehicle-controlled, intrapatient study was designed to further characterize the MOA of crisaborole through evaluation of clinical efficacy and changes in skin biomarkers in adults (N = 40) with mild-to-moderate AD.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

242 Samples

Download data: CEL

(Submitter supplied) Background: While atopic dermatitis (AD) often starts in early childhood, detailed tissue profiling of early-onset AD in children is lacking, hindering therapeutic development for this patient population with a particularly high unmet need of better treatments. Objective: We sought to globally profile the skin of infants with AD compared to adults with AD and healthy controls. Methods: We performed microarray, RT-PCR and fluorescence microscopy studies in infants and young children (<5yo) with early-onset AD (<6mo) compared to age-matched controls and adults with longstanding AD. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

108 Samples

Download data: CEL

(Submitter supplied) To gain a deeper understanding of the pathophysiology of AD, we conducted a large-scale transcriptomic study of AD with deeply-sequenced RNA-seq samples using long (125b) paired-end reads. By integrating deep sequencing-based skin transcriptome profiling with systems biology analysis, we are able to provide deep characterization for the expression signatures for AD.

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL16791

33 Samples

Download data: TXT

(Submitter supplied) To gain a deeper understanding of the pathophysiology of AD, we conducted a large-scale transcriptomic study of AD with deeply-sequenced RNA-seq samples using long (125b) paired-end reads. By integrating deep sequencing-based skin transcriptome profiling with systems biology analysis, we are able to provide deep characterization for the expression signatures for AD, and by including psoriasis samples in the analysis, we can reveal the distinct molecular features of uninvolved and lesional skin of AD that have not been previously described.

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL16791

147 Samples

Download data: TXT

(Submitter supplied) Atopic dermatitis (AD) is the most common inflammatory skin disease, with high unmet need for new therapies that are safe for chronic use. Emerging data suggest that TH2-cytokines play important roles in a variety of allergic and atopic conditions, including asthma and AD. In early phase clinical trials, dupilumab (a fully human monoclonal antibody against IL-4Rα that potently blocks IL-4 and IL-13 signaling) rapidly and markedly improved clinical measures in adults with either asthma (with elevated eosinophil counts) or moderate-to-severe AD. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

40 Samples

Download data: CEL

(Submitter supplied) This is the first report that establishes robust epidermal and dermal genomic signatures of lesional and nonlesional AD skin and normal skin compared with whole tissues. These data establish the utility of laser capture microdissection to separate different compartments and cellular subsets in patients with AD, allowing localization of key barrier or immune molecules and enabling detection of gene products usually not detected on arrays.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

52 Samples

Download data: CEL

(Submitter supplied) In this study we used genomic profiling to characterize differences in expression of genes related to epidermal growth/differentiation and inflammatory circuits in skin lesions of psoriasis and atopic dermatitis (AD), comparing expression values to normal skin. Skin biopsies were collected from 9 patients with chronic atopic dermatitis, 15 psoriasis patients, and 9 healthy volunteers. Keywords: Genetic-pathology

Organism:

Homo sapiens

Type:

Expression profiling by array

Platforms:

GPL571 GPL570

33 Samples

Download data: CEL, TXT

(Submitter supplied) Background: Atopic dermatitis (AD) is a prevalent inflammatory skin disease with a complex pathogenesis, involving immune cell and epidermal abnormalities. Despite whole tissue biopsy studies that have advanced the mechanistic understanding of AD, single-cell-based molecular alterations are largely unknown. Objective: To construct a detailed, high-resolution atlas of cell populations, and to assess variability in cell composition and cell-specific gene expression in the skin of AD patients versus controls. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL16791

17 Samples

Download data: TXT

(Submitter supplied) This study includes RNAseq data of lesional and autologous non-lesional skin from patients with non-communicable inflammatory skin diseases, including psoriasis, nummular eczema and atopic dermatitis.

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL20301

376 Samples

Download data: TXT